Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–3 of 3 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Solid Tumors, HER2-positive Breast Cancer
Interventions
ZN-A-1041, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1c, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Tucson, Arizona • Cerritos, California • San Francisco, California + 5 more
Conditions
HER2-positive Breast Cancer
Interventions
RO7771950, Tucatinib, Trastuzumab, Capecitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
14
States / cities
Huntsville, Alabama • Gilbert, Arizona • San Francisco, California + 10 more
Conditions
Healthy Volunteers
Interventions
ZN-A-1041 Formulation 1, ZN-A-1041 Formulation 2, Rabeprazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas